Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Identifieur interne : 001765 ( Main/Corpus ); précédent : 001764; suivant : 001766Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Auteurs : Omer Gendelman ; Howard Amital ; Nicola Luigi Bragazzi ; Abdulla Watad ; Gabriel ChodickSource :
- Autoimmunity reviews [ 1873-0183 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), Chemoprevention (MeSH), Colchicine (therapeutic use), Coronavirus Infections (prevention & control), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Israel (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (prevention & control), Pneumonia, Viral (prevention & control), Retrospective Studies (MeSH), SARS-CoV-2 (MeSH), Treatment Failure (MeSH).
- MESH :
- chemical , therapeutic use : Colchicine, Hydroxychloroquine.
- geographic : Israel.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- Adult, Betacoronavirus, COVID-19, Chemoprevention, Female, Humans, Male, Middle Aged, Retrospective Studies, SARS-CoV-2, Treatment Failure.
Abstract
BACKGROUND
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.
METHODS
This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.
RESULTS
An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).
CONCLUSION
These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
DOI: 10.1016/j.autrev.2020.102566
PubMed: 32380315
PubMed Central: PMC7198406
Links to Exploration step
pubmed:32380315Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.</title><author><name sortKey="Gendelman, Omer" sort="Gendelman, Omer" uniqKey="Gendelman O" first="Omer" last="Gendelman">Omer Gendelman</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Amital, Howard" sort="Amital, Howard" uniqKey="Amital H" first="Howard" last="Amital">Howard Amital</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: howard.amital@sheba.health.gov.il.</nlm:affiliation></affiliation></author><author><name sortKey="Bragazzi, Nicola Luigi" sort="Bragazzi, Nicola Luigi" uniqKey="Bragazzi N" first="Nicola Luigi" last="Bragazzi">Nicola Luigi Bragazzi</name><affiliation><nlm:affiliation>Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, ON M3J 1P3, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Watad, Abdulla" sort="Watad, Abdulla" uniqKey="Watad A" first="Abdulla" last="Watad">Abdulla Watad</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Chodick, Gabriel" sort="Chodick, Gabriel" uniqKey="Chodick G" first="Gabriel" last="Chodick">Gabriel Chodick</name><affiliation><nlm:affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32380315</idno><idno type="pmid">32380315</idno><idno type="doi">10.1016/j.autrev.2020.102566</idno><idno type="pmc">PMC7198406</idno><idno type="wicri:Area/Main/Corpus">001765</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001765</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.</title><author><name sortKey="Gendelman, Omer" sort="Gendelman, Omer" uniqKey="Gendelman O" first="Omer" last="Gendelman">Omer Gendelman</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Amital, Howard" sort="Amital, Howard" uniqKey="Amital H" first="Howard" last="Amital">Howard Amital</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: howard.amital@sheba.health.gov.il.</nlm:affiliation></affiliation></author><author><name sortKey="Bragazzi, Nicola Luigi" sort="Bragazzi, Nicola Luigi" uniqKey="Bragazzi N" first="Nicola Luigi" last="Bragazzi">Nicola Luigi Bragazzi</name><affiliation><nlm:affiliation>Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, ON M3J 1P3, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Watad, Abdulla" sort="Watad, Abdulla" uniqKey="Watad A" first="Abdulla" last="Watad">Abdulla Watad</name><affiliation><nlm:affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Chodick, Gabriel" sort="Chodick, Gabriel" uniqKey="Chodick G" first="Gabriel" last="Chodick">Gabriel Chodick</name><affiliation><nlm:affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Autoimmunity reviews</title><idno type="eISSN">1873-0183</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chemoprevention (MeSH)</term><term>Colchicine (therapeutic use)</term><term>Coronavirus Infections (prevention & control)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Israel (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (prevention & control)</term><term>Retrospective Studies (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Treatment Failure (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Colchicine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Israel</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Chemoprevention</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>SARS-CoV-2</term><term>Treatment Failure</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32380315</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-0183</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Autoimmunity reviews</Title><ISOAbbreviation>Autoimmun Rev</ISOAbbreviation></Journal><ArticleTitle>Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.</ArticleTitle><Pagination><MedlinePgn>102566</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1568-9972(20)30128-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.autrev.2020.102566</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gendelman</LastName><ForeName>Omer</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amital</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: howard.amital@sheba.health.gov.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bragazzi</LastName><ForeName>Nicola Luigi</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, ON M3J 1P3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watad</LastName><ForeName>Abdulla</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chodick</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Maccabitech, Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Autoimmun Rev</MedlineTA><NlmUniqueID>101128967</NlmUniqueID><ISSNLinking>1568-9972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber><NameOfSubstance UI="D003078">Colchicine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Colchicine</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Rheumatic disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32380315</ArticleId><ArticleId IdType="pii">S1568-9972(20)30128-2</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2020.102566</ArticleId><ArticleId IdType="pmc">PMC7198406</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Res Cardiol. 2020 May;109(5):531-538</Citation><ArticleIdList><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Mar 26;368:m1198</Citation><ArticleIdList><ArticleId IdType="pubmed">32217618</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr Med Assoc J. 2020 Apr;22(4):211-213</Citation><ArticleIdList><ArticleId IdType="pubmed">32286020</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32181795</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Apr 14;369:m1483</Citation><ArticleIdList><ArticleId IdType="pubmed">32291262</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr Med Assoc J. 2020 Apr;22(4):214-215</Citation><ArticleIdList><ArticleId IdType="pubmed">32286021</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 May;94:91-95</Citation><ArticleIdList><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346</Citation><ArticleIdList><ArticleId IdType="pubmed">32214079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2018;24(6):684-689</Citation><ArticleIdList><ArticleId IdType="pubmed">29336252</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2017 Aug 25;17(1):589</Citation><ArticleIdList><ArticleId IdType="pubmed">28841914</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Arthritis Rheum. 2015 Dec;45(3):341-50</Citation><ArticleIdList><ArticleId IdType="pubmed">26228647</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):e67</Citation><ArticleIdList><ArticleId IdType="pubmed">32348666</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464</Citation><ArticleIdList><ArticleId IdType="pubmed">32298251</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Mol Med. 2020 May;26(5):483-495</Citation><ArticleIdList><ArticleId IdType="pubmed">32359479</ArticleId></ArticleIdList></Reference><Reference><Citation>Intern Med J. 2012 Sep;42(9):968-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22827853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Apr 11;395(10231):1168</Citation><ArticleIdList><ArticleId IdType="pubmed">32278370</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation><ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386</Citation><ArticleIdList><ArticleId IdType="pubmed">32240123</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatol Int. 2019 Mar;39(3):517-523</Citation><ArticleIdList><ArticleId IdType="pubmed">30604205</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr Med Assoc J. 2020 Apr;22(4):203-210</Citation><ArticleIdList><ArticleId IdType="pubmed">32286019</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Res Ther. 2009;11(4):R109</Citation><ArticleIdList><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2020 Apr 18;215:108426</Citation><ArticleIdList><ArticleId IdType="pubmed">32311462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenic J Cardiol. 2020 Apr 3;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32251729</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmun Rev. 2020 Jun;19(6):102538</Citation><ArticleIdList><ArticleId IdType="pubmed">32268212</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 13;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001765 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001765 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32380315
|texte= Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32380315" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |